Iveric's Zimura Shows Benefit In Geographic Atrophy, An Area Poised For New Options
The company plans to file the complement C5 inhibitor with the US FDA, but Apellis already has a drug pending for the indication.
You may also be interested in...
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.
The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.